In this context, glibenclamide, an ATP-sensitive potassium channel blocker, should be tested for progressive MS, because it decreases the production of proinflammatory mediators (Tumor necrosis factor [TNF-α], IL-1β, and reactive oxygen species) and the accumulation of inflammatory cells (50). Here, TNF is linked to myeloid sarcoma.